Denali Therapeutics Inc. Stock




Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT 5-day change 1st Jan Change
22.63 USD +5.75% Intraday chart for Denali Therapeutics Inc. +9.17% +5.45%
Sales 2024 * 45.66M 62.52M Sales 2025 * 107M 146M Capitalization 3.23B 4.42B
Net income 2024 * -426M -583M Net income 2025 * -464M -635M EV / Sales 2024 * 43.2 x
Net cash position 2024 * 1.25B 1.72B Net cash position 2025 * 1.05B 1.44B EV / Sales 2025 * 20.4 x
P/E ratio 2024 *
-8.25 x
P/E ratio 2025 *
-8.27 x
Employees 375
Yield 2024 *
Yield 2025 *
Free-Float 86.28%
More Fundamentals * Assessed data
Dynamic Chart
Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors and Chairperson of Audit Committee CI
Denali Therapeutics' Enzyme Replacement Therapy Picked for FDA's START Pilot Program; Shares Rise MT
Denali Therapeutics Inc. Announces FDA Selects DNL126 for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies CI
Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating MT
Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating MT
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial CI
UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating MT
Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing MT
Denali Therapeutics Files Prospectus for Secondary Offering MT
Denali Therapeutics Inc. announced that it has received $499.73271 million in funding from Baker Bros. Advisors LP and other investors CI
B. Riley Securities Adjusts Denali Therapeutics' Price Target to $36 From $38, Keeps Buy Rating MT
Denali Shares Rise on PIPE Deal, Plan to Spin Out Preclinical Small Molecule Portfolio MT
Denali Q4 Net Loss Widens; Launching PIPE Deal, Plans to Spin Out Preclinical Small Molecule Portfolio; Shares Jump Pre-Bell MT
Denali Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
More news
1 day+5.75%
1 week+9.17%
Current month+21.93%
1 month+12.81%
3 months+15.34%
6 months+3.05%
Current year+5.45%
More quotes
1 week
Extreme 19.735
1 month
Extreme 17.93
Current year
Extreme 14.56
1 year
Extreme 14.56
3 years
Extreme 14.56
5 years
Extreme 12.39
10 years
Extreme 12.32
More quotes
Managers TitleAgeSince
Founder 50 13-10-13
Founder 48 13-10-13
Chief Tech/Sci/R&D Officer - 19-12-31
Members of the board TitleAgeSince
Chairman 75 15-03-31
Director/Board Member 71 15-03-31
Director/Board Member 66 15-03-31
More insiders
Date Price Change Volume
24-06-21 22.63 +5.75% 5,205,747
24-06-20 21.4 +3.78% 1,127,330
24-06-18 20.62 +0.68% 928,691
24-06-17 20.48 -1.21% 1,235,143

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm

More quotes
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
22.63 USD
Average target price
38.67 USD
Spread / Average Target